Institute for Ethics and Emerging Technologies

The IEET is a 501(c)3 non-profit, tax-exempt organization registered in the State of Connecticut in the United States. Please give as you are able, and help support our work for a brighter future.

Search the IEET
Subscribe and Contribute to:

Technoprogressive? BioConservative? Huh?
Quick overview of biopolitical points of view

whats new at ieet

A.I. Can Pretend to Love Us, but is that Dangerous for Children?

Keynote: “Eternal Progression”

A for Almighty - Fred Hoyle’s Cosmic Theology

This is your brain on communication

L’absurde peur du temps libre

Capital Lust, Not Capitalism, is Destroying the Earth and the Economy - See more at: http://ehumanda

ieet books

Philosophical Ethics: Theory and Practice
John G Messerly


Peter Wicks on 'Will World War 3 Be Prevented Because of Global Interdependence?' (Jun 1, 2016)

instamatic on 'Will World War 3 Be Prevented Because of Global Interdependence?' (May 31, 2016)

Peter Wicks on 'Will World War 3 Be Prevented Because of Global Interdependence?' (May 31, 2016)

spud100 on 'Will World War 3 Be Prevented Because of Global Interdependence?' (May 30, 2016)

Peter Wicks on 'Will World War 3 Be Prevented Because of Global Interdependence?' (May 30, 2016)

instamatic on 'Will World War 3 Be Prevented Because of Global Interdependence?' (May 29, 2016)

Peter Wicks on 'Will World War 3 Be Prevented Because of Global Interdependence?' (May 29, 2016)

Subscribe to IEET News Lists

Daily News Feed

Longevity Dividend List

Catastrophic Risks List

Biopolitics of Popular Culture List

Technoprogressive List

Trans-Spirit List


Enframing the Flesh: Heidegger, Transhumanism, and the Body as “Standing Reserve”

Moral Enhancement and Political Realism

Intelligent Technologies and Lost Life

Hottest Articles of the Last Month

Ethicists Generally Agree: The Pro-Life Arguments Are Worthless
May 17, 2016
(4375) Hits
(10) Comments

Artificial Intelligence in the UK: Risks and Rewards
May 12, 2016
(3409) Hits
(0) Comments

Nicotine Gum for Depression and Anxiety
May 5, 2016
(3076) Hits
(0) Comments

Guaranteed Mirage Income?
May 14, 2016
(2954) Hits
(2) Comments

IEET > Security > SciTech > Life > Innovation > Health > Contributors > Andrew Maynard

Print Email permalink (4) Comments (21798) Hits •  subscribe Share on facebook Stumble This submit to reddit submit to digg

Nanotechnology and Cancer Treatment

Andrew Maynard
By Andrew Maynard
2020 Science

Posted: Mar 7, 2010

Do we need a reality check?

Cancer treatment has been a poster-child for nanotechnology for almost as long as I’ve been involved with the field. As far back as in 1999, a brochure on nanotechnology published by the US government described future “synthetic anti-body-like nanoscale drugs or devices that might seek out and destroy malignant cells wherever they might be in the body.” 

imageOver the intervening decade, nanotechnology has become a cornerstone of the National Cancer Institute’s fight against cancer, and has featured prominently in the US government’s support for nanotechnology research and development. And for good reason – nanotechnology holds the promise of treatments that can diagnose cancer earlier in the disease’s development than ever before; treat tumors using lower concentrations of chemotherapy agents, and target malignant cells while leaving healthy cells untouched.

Like many of my colleagues, I have used emerging nanotechnology-based cancer treatments as a compelling example of what is possible when we gain mastery over materials at the scale of the atoms and molecules they are made of. So I was somewhat surprised to see the eminent chemist and nano-scientist George Whitesides questioning how much progress we’ve made in developing nanotechnology-based cancer treatments, in an article published in the Columbia Chronicle.

According to the article:

George Whitesides, professor of chemistry and chemical biology at Harvard University, said that while the technology sounds impressive, he thinks the focus should be on using nanoparticles in imaging and diagnosing, not treatment.

The problem lies in being able to deliver the treatment to the right cells, and Whitesides said this has proven difficult. “Cancer cells are abnormal cells, but they’re still us,” he said.

Whitesides went on to comment that:

“It’s easy to say that one is going to have a particle that’s going to recognize the tumor once it gets there and will do something that triggers the death of the cell, it’s just that we don’t know how to do either one of these parts.”

This got me thinking – because George is a smart guy and well worth paying attention to – have we somehow got so caught up in the possibilities of nanotechnology in treating cancer, that we have lost sight of the realities?

To get a better sense of where we are on nanotech-enabled approaches to treating cancer, I asked a handful of experts working in the field the following question:

What are some of the more significant science challenges researchers face in developing nanotechnology-based cancer treatments?

The responses were cautious, and clearly cognizant of the hurdles to taking scientific and technological breakthroughs out of the lab and into the market. Yet despite this, there was an over-riding sense of optimism running through them.

Steve Rosen, Director of the Robert H. Lurie Comprehensive Cancer Center at Northwestern University commented:

“I feel nanotechnology has the possibility of revolutionizing both in vitro and in vivo cancer diagnostics.  Therapy always remains a greater challenge and in the short term I see nanotechnology as a vehicle to enhanced delivery. The long term prospects are substantial and limited only by the creativity of individuals involve in this area of investigation.”

This was echoed by Tyler Jacks, Director, David H. Koch Institute for Integrative Cancer Research at MIT:

“Nanotechnology holds great promise for cancer therapy, in my view. That said, there is need for more research to learn the best strategies to specifically direct the nanomaterials to cancer cells following systemic administration. This will require overcoming the body’s natural filtration systems as well as optimizing the methods for tumor-specific targeting. It may be that truly tumor-specific targeting will require combinatorial approaches.”

The difficulties of overcoming biological barriers to using nanoparticles effectively in treating cancers were expanded on by Martin Philbert, Senior Associate Dean at School of Public Health, University of Michigan:

“The body’s immune system is primed to recognize particles of the size range encompassed by most therapeutic and imaging nanotechnologies.  Since elements of the immune system are coordinated and disseminated throughout the body, a major challenge is the design and fabrication of nanotechnologies that will either avoid immune cells or use them to achieve appropriate targeting without activation or suppression of immune function.

“A second major hurdle is elimination from the body.  Many of the newer nanoparticles are designed to be eliminated from the body by either being ’small’, i.e., less than 8 nm in diameter to facilitate passage with the urine out of the kidneys, or to dissolve to a size that allows for elimination through the urinary flow.  Nevertheless, the kinetics of elimination are invariably altered by the ability of the reticuloendothelial portion of the immune system to take up these materials and sequester them in lymphatic organs or interstitial spaces for longer periods than anticipated.”

Yet despite the challenges, progress is clearly being made. Piotr Grodzinsky, Director, Nanotechnology Cancer Programs at the National Cancer Institute noted that:

“Nanotechnologies for medical applications have been maturing. Several therapeutic formulations entered clinical trials and are expected to have an impact on how cancer treatment is done in the future. Similarly, multiplex diagnostic platforms with high sensitivity and specificity are proving themselves in testing of clinical specimens and will contribute to early disease detection.”

Scott McNeil, Director of the Nanotechnology Characterization Laboratory cautioned that:

“Developers of nanotech-based therapeutics face preclinical challenges that may be more involved than development of small molecule drugs…”

But went on to add:

“…the payoffs are now being demonstrated in clinical trials by several companies. We are observing a consistent trend towards decreased toxicity for nanodrugs compared to their small molecule counterparts.”

And in responding specifically to Whitesides’ comments, Jim Baker, Director of the Michigan Nanotechnology Institute for Medicine and the Biological Sciences, observed that:

“[George Whitesides] is correct that this is a very complex problem, with cancer as a variation of self being a central issue. In addition, the concept of some in the material science community that nanoscale materials would be inherently better ignores potential problems related to biocompatibility and the necessity of this material to function in a wet environment. Additionally, the concept of a “nanomachine” is fundamentally flawed because having mechanical devices of this size violates the laws of physics. What is moving forward are bio-inspired materials that will provide incremental improvements in drug delivery and imaging that could not be accomplished with traditional materials. Each one will be unique, however, and require its own evaluation for efficacy and toxicity, just like any other drug. This provides a difficult hurdle, given the costs and clinical evaluations that are involved.”

Reading through these comments, I get the sense that we’re only beginning to scratch the surface of what working at the nanoscale can do for cancer treatment. Certainly there are hurdles to be overcome – some of them significant. And it’s important to remember that the road between lab-based discoveries and real-world treatments is a long and arduous one – even the most promising therapies can take years or even decades to get to the point where they are widely available.

Yet it’s hard to avoid being caught up in the enthusiasm of scientists working on nanotechnology-enabled cancer treatments, or not to be inspired by what might be achieved through engineering increasingly sophisticated therapeutics at the nanoscale.

That said, expectations on how nanotechnology will impact cancer treatment clearly need to be tempered. In this respect, I thought that the comments from Jennifer West, the Isabel C. Cameron Professor of Bioengineering at Rice University, were particularly well-grounded:

“Nanotechnology isn’t a magic solution to cancer, but provides additional tools in the arsenal, some with new and unique properties. As with any cancer therapy, the key issue is to get the therapeutic agent to tumor sites and metastases at high concentrations, then destroy cancerous cells while minimizing damage to normal cells.”

Nanotechnology is clearly not a panacea. It provides exciting new opportunities for treating cancer. But its use also faces many scientific, economic and regulatory hurdles.

Yet the idea of crafting more effective cancer treatments by engineering matter at the nanoscale remains a compelling one – if only we can work out how to translate the idea into practical solutions.

As one of my sources – who preferred not to be named – commented:

“I don’t think that the field needs a reality check but rather ways to move more of the discoveries and developments into humans.”

Andrew Maynard is Director of the Risk Science Center at the University of Michigan School of Public Health.
Print Email permalink (4) Comments (21799) Hits •  subscribe Share on facebook Stumble This submit to reddit submit to digg


Being a person with cancer, the potential of nanotechnology to be utilized in cancer treatment is exciting. I have papillary thyroid cancer, tall cell variant, whcih is diffiuclt to treat. Thyroid cancers are immune to chemotherapy treatments, the main treatment is radiation/ iodine treatment. If the cancer becomes immune to this treatment there are few options avaliable.

Dr Langer from the MIT Koch cancer center is going to begin human clinical trials this year using nanotechnology in the treatment of prostate cancer. In his lab trails using rats and mice implanted with prostate cancer they were able to cure the animals of cancer using nanotechnology.

Hopefully there will be human trials availble using nanos to treat thyroid cancer in the near future.


My wife is suffering from panreatic NET.
Its irresectable and she is only 27 yrs. Being engineer i use to wonder if any non conventional way is available/can be trialed to get rid of cancerous cells. Nano tec. was on top of my list, but i have very limited knowledge of this area.

Seeing he go through bouts of nausea, diarrohea and hair fall makes me sad, any help on applicability of Nano Tech. for her treatment would be highly appreciated.

I think that nanotechnology can only work once a method is found to kill the cancerous cells first. If we are using the same chemicals and methods of treatment as before, except this time they are in a small capsule hardly the width of pin; then treatment has actually gotten nowhere.

Many chemotherapy drugs could potentially kill the cancer cells if they could be administered in sufficient strength. However, because of toxicity concerns for the patient, the drug can’t be given in such a strong dosage. This is where nanotechnology could potentially come in. If you could somehow target the drug to the tumor while sparing healthy cells, you could deliver dosages that are extremely toxic to the tumor.

YOUR COMMENT (IEET's comment policy)

Login or Register to post a comment.

Next entry: A Probabilistic Characterization of Fuzzy Set Membership…

Previous entry: Artificial Brains: a Review of the State of the Art and a Roadmap for Future Development


RSSIEET Blog | email list | newsletter |
The IEET is a 501(c)3 non-profit, tax-exempt organization registered in the State of Connecticut in the United States.

East Coast Contact: Executive Director, Dr. James J. Hughes,
56 Daleville School Rd., Willington CT 06279 USA 
Email: director @     phone: 860-428-1837

West Coast Contact: Managing Director, Hank Pellissier
425 Moraga Avenue, Piedmont, CA 94611
Email: hank @